Tirzepatide 5 mg: First Therapeutic Dose (Weeks 5-8 or Maintenance)
5 mg is where tirzepatide starts producing real therapeutic effect. SURMOUNT-1 showed 15% mean body weight reduction at this dose — making it a clinically valid long-term maintenance setpoint for many patients.
Tirzepatide 5 mg weekly is the second step in the Zepbound titration (weeks 5-8) and the first dose at which therapeutic effect feels meaningful. SURMOUNT-1 NEJM 2022 reported 15.0% mean body weight reduction at the 5 mg maintenance dose — only modestly less than the 19.5% (10 mg) and 20.9% (15 mg) achieved at higher doses. Many patients maintain at 5 mg long-term, trading some additional weight loss potential for fewer side effects.
SURMOUNT-1 data at 5 mg
| Group | Mean % body weight loss (72 wks) | % of patients losing >5% |
|---|---|---|
| Tirzepatide 5 mg | 15.0% | 85% |
| Tirzepatide 10 mg | 19.5% | 89% |
| Tirzepatide 15 mg | 20.9% | 91% |
| Placebo | 3.1% | 35% |
Note: 15.0% at 5 mg is approximately equivalent to Wegovy's STEP 1 result for semaglutide 2.4 mg (14.9%) — but at a lower dose level, suggesting tirzepatide's dual GIP/GLP-1 mechanism is more potent per mg than semaglutide's GLP-1-only mechanism.
5 mg as a long-term maintenance option
Increasingly common clinical pattern: patients reach 5 mg and choose to maintain there rather than escalating to 7.5/10/15 mg. The trade-off:
- 5 mg: 15% mean weight loss, moderate side effects, lower "Ozempic face" risk from slower loss
- 15 mg max: 20.9% mean weight loss, more frequent GI symptoms, higher rate of rapid loss
For patients near goal weight, with adequate appetite suppression at 5 mg, holding at 5 mg long-term is clinically reasonable. Trimi clinicians support this individualization.
Continue tirzepatide titration with Trimi
$125/month annual plan, flat across all titration doses (2.5-15 mg). Same active ingredient as Zepbound and Mounjaro.
Start your visitFAQs
Is 5 mg tirzepatide enough for weight loss?
For many patients yes. 5 mg is the first therapeutic dose in the tirzepatide titration — clinical effect begins to feel meaningful here. SURMOUNT-1 NEJM 2022 showed 15.0% mean body weight reduction at 5 mg (vs 19.5% at 10 mg, 20.9% at 15 mg). Many real-world patients maintain at 5 mg long-term with strong appetite suppression and steady weight loss.
When do I escalate to tirzepatide 5 mg?
Week 5, per the standard Zepbound/Mounjaro titration. After 4 weeks at the 2.5 mg starter dose, clinicians typically escalate to 5 mg weekly. This doubles the GIP/GLP-1 receptor activation and significantly increases appetite suppression for most patients.
How much weight loss should I expect at 5 mg?
SURMOUNT-1 results at 72 weeks: 5 mg dose group achieved 15.0% mean weight loss vs 3.1% placebo. Most patients on 5 mg for 4-8 weeks see 5-10 lbs of loss during this titration block on top of cumulative loss from earlier weeks.
Side effects at 5 mg tirzepatide?
Each titration step transiently increases GI symptoms for 5-10 days post-dose-change. Nausea (24-25% in SURMOUNT-1 5 mg group), diarrhea (~17%), vomiting (~7-9%), constipation (~10%) are most common. Severe symptoms warrant slowing escalation or holding at 5 mg longer.
Can I stay at 5 mg as my maintenance dose?
Yes — increasingly popular choice. Patients responding well to 5 mg (strong appetite suppression, steady weight loss, mild side effects) often maintain at 5 mg rather than escalating to higher doses. The trade-off: 15% mean weight loss at 5 mg vs 20.9% at 15 mg, but fewer side effects and lower 'Ozempic face' risk from slower rate of loss. Discuss long-term setpoint with your Trimi clinician.
Is compounded tirzepatide 5 mg same as Zepbound 5 mg?
Same active ingredient at the same weekly dose. Zepbound 5 mg is a pre-filled pen autoinjector; compounded tirzepatide via Trimi is drawn from a vial into a syringe. The tirzepatide molecule and dose are identical.
Related reading
Disclaimer: Informational, not medical advice. Trial citation: Jastreboff AM et al, NEJM 2022 (SURMOUNT-1). Compounded tirzepatide is prepared per individual prescription by a 503A community sterile compounding pharmacy; not FDA-approved as a finished drug. **The FDA does not review or approve any compounded medications for safety or effectiveness.